Focus on Anticoagulation Care

Back to articles

Bleeding risk with anticoagulants underestimated in clinical trials

KEY POINT

A review of data from patients in a commercial health care claims database who were initiating either warfarin or dabigatran (Pradaxa—Boehringer Ingelheim) for atrial fibrillation (AF) found that the risks of thromboembolism was similar to those estimated by clinical trials; however, the risk of major bleeding with these agents was much higher in practice.